EA200701669A1 - Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae - Google Patents

Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae

Info

Publication number
EA200701669A1
EA200701669A1 EA200701669A EA200701669A EA200701669A1 EA 200701669 A1 EA200701669 A1 EA 200701669A1 EA 200701669 A EA200701669 A EA 200701669A EA 200701669 A EA200701669 A EA 200701669A EA 200701669 A1 EA200701669 A1 EA 200701669A1
Authority
EA
Eurasian Patent Office
Prior art keywords
infections caused
viruses
compositions
prevention
treatment
Prior art date
Application number
EA200701669A
Other languages
English (en)
Inventor
Доминик Дюгуа
Эвелина Рубинчик
Якоб Клеман
Хилел Дэвид Фридлэнд
Original Assignee
Мидженикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мидженикс Инк. filed Critical Мидженикс Инк.
Publication of EA200701669A1 publication Critical patent/EA200701669A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее описание относится, в общем, к композициям, содержащим ингибитор глюкозидазы (кастаноспермин или его производное, такое как селгосивир) в сочетании со вспомогательными лекарственными средствами или соединениями, изменяющими иммунную функцию (такими как интерферон), и соединениями, изменяющими репликацию вируса (такими как нуклеозидные аналоги, подобные рибавирину), которые можно применять для лечения или предотвращения инфекций, вызванных или связанных с вирусом семейства Flaviviridae, особенно инфекций, вызванных или связанных с вирусом гепатита С (ВГС).
EA200701669A 2005-02-09 2006-02-09 Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae EA200701669A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65191005P 2005-02-09 2005-02-09
US66429705P 2005-03-21 2005-03-21
US73546405P 2005-11-12 2005-11-12
PCT/US2006/004927 WO2006096285A2 (en) 2005-02-09 2006-02-09 Compositions and methods for treating or preventing flaviviridae infections

Publications (1)

Publication Number Publication Date
EA200701669A1 true EA200701669A1 (ru) 2008-02-28

Family

ID=36953799

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701669A EA200701669A1 (ru) 2005-02-09 2006-02-09 Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae

Country Status (11)

Country Link
US (1) US20060194835A1 (ru)
EP (1) EP1853317A2 (ru)
JP (1) JP2008530124A (ru)
KR (1) KR20070102741A (ru)
CN (1) CN101304762A (ru)
AU (1) AU2006221080A1 (ru)
CA (1) CA2597213A1 (ru)
EA (1) EA200701669A1 (ru)
IL (1) IL185056A0 (ru)
MX (1) MX2007009561A (ru)
WO (1) WO2006096285A2 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
JP2009545621A (ja) * 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
JP2010510171A (ja) * 2006-08-21 2010-04-02 ユナイテッド セラピューティクス コーポレーション ウイルス感染症の治療のための併用療法
TW200815384A (en) * 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
EP2293671A4 (en) * 2008-06-03 2012-03-21 Siga Technologies Inc SMALL MOLECULAR INHIBITORS FOR TREATING OR PREVENTING DENGUE INFECTIONS
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US10328061B2 (en) * 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190530A (es) 2017-05-22 2020-01-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
JP7179773B2 (ja) 2017-05-22 2022-11-29 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
US20230285435A1 (en) * 2020-07-17 2023-09-14 The Regents Of The University Of California Compositions and methods for treating viral infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883925B (en) * 1987-06-08 1989-02-22 Merrell Dow Pharma Inhibitors of glycoprotein processing having anti-retroviral activity
AU2001234596A1 (en) * 2000-01-28 2001-08-07 Timothy M Block Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
AU2005291804A1 (en) * 2004-10-06 2006-04-13 Migenix Inc. Combination anti-viral compositions comprising castanospermine and methods of use

Also Published As

Publication number Publication date
JP2008530124A (ja) 2008-08-07
WO2006096285A3 (en) 2007-01-25
AU2006221080A1 (en) 2006-09-14
CN101304762A (zh) 2008-11-12
EP1853317A2 (en) 2007-11-14
US20060194835A1 (en) 2006-08-31
MX2007009561A (es) 2008-01-14
IL185056A0 (en) 2007-12-03
WO2006096285A2 (en) 2006-09-14
CA2597213A1 (en) 2006-09-14
KR20070102741A (ko) 2007-10-19

Similar Documents

Publication Publication Date Title
EA200701669A1 (ru) Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
PL1987038T3 (pl) Inhibitory HCV NS5B
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
HK1122291A1 (en) Anti-viral compounds
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
EA200700243A1 (ru) Способы лечения гепатита с
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
EA200900297A1 (ru) Ингибиторы вируса гепатита с
ATE475660T1 (de) Antivirale verbindungen
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
ATE474827T1 (de) Hcv-replikationshemmer
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
CY1112699T1 (el) Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
NO20080879L (no) HCV-NS3-proteaseinhibitorer
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
EA200700718A1 (ru) Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
TW200631585A (en) 5-nitro-nucleoside compounds for treating viral infections
TW200614989A (en) Inhibitors of HCV replication